Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.
about
Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseTrimethylamine N-Oxide: The Good, the Bad and the UnknownThe systemic nature of CKD.Volatile organic compounds in uremia.Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.Metabolite profiling identifies markers of uremia.Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational StudyA modern approach to the treatment of mitochondrial diseaseGut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney diseaseRole of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease.Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production.A colorimetric sensor for qualitative discrimination and quantitative detection of volatile amines.Determination of trimethylamine-N-oxide in combination with L-carnitine and γ-butyrobetaine in human plasma by UPLC/MS/MS.Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to DialysisMetabolomics and renal disease.Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis.Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis PatientsSerum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney DiseaseMetabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosisSerum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional studyTrimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.Genetic Variant in Flavin-Containing Monooxygenase 3 Alters Lipid Metabolism in Laying Hens in a Diet-Specific Manner.Microbiota-Dependent Metabolite Trimethylamine N-Oxide and Coronary Artery Calcium in the Coronary Artery Risk Development in Young Adults Study (CARDIA)SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammationNormal and pathologic concentrations of uremic toxins.Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis.Inflammation and L-carnitine therapy in hemodialysis patients: a review.Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment.Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies.Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies.The complex metabolism of trimethylamine in humans: endogenous and exogenous sources.Trimethylamine-N-Oxide Treatment Induces Changes in the ATP-Binding Cassette Transporter A1 and Scavenger Receptor A1 in Murine Macrophage J774A.1 cells.Microbiome, trimethylamine N-oxide, and cardiometabolic disease.Trimethylamine N-oxide: breathe new life.Molecular signatures of ovarian diseases: Insights from network medicine perspective.Trimethylamine N-oxide and prognosis in acute heart failure.A metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS).
P2860
Q24601951-6D50A83E-D4BA-42C3-8998-E5828ABCB58EQ28079182-842A6150-4E71-4D71-BE9B-7D6526839821Q30234695-63222CC9-4E48-4CD9-B997-A3DC225E95ACQ31104730-53989AB9-CB08-4BB7-8517-6B9571B2F39AQ33749467-D507F065-A472-48BB-B5FC-A9B05CE09DF4Q33979275-FC55FA63-7435-41F7-9D84-D749C0EF61DFQ34672965-DE019127-EDBD-485A-8584-260AC815899EQ35011397-45590FA6-545F-48CD-A3D6-611A58F8CC57Q35033613-5F2F92B9-9985-475B-9BF4-9B705EE9D14FQ35156688-B69B5F05-72A4-49B6-8FCB-58444511BFCDQ35232161-6A3DD5FA-8DB2-4F9A-A684-A51BA17A9C0FQ35406034-C6798A69-4FFA-4D05-9516-369A35BEF2F4Q35458175-107C154E-2FDD-4619-BB62-830EB12623F9Q35593884-5310EB99-220E-43C0-959B-78A8EA04A449Q35601213-6BACBEEF-DF97-4CFF-AAC0-D5049AE1D89BQ35748583-EF75FC4D-EA53-425D-AAFB-D86B095632B4Q35778649-E08ED113-78FF-45E6-A9BD-13C712022A20Q35798608-1C28AECD-E633-4227-BF42-7F08B674119BQ35864491-3C61B62F-24AF-46FD-8C58-540712106761Q35889821-183F70F7-C0C6-4934-AA4C-453DFF3F4FC6Q36100197-DAD05AD3-D413-420A-8055-71AAAB662EC7Q36417895-D760D272-07AA-4241-BFA5-8B144582C445Q37310131-A075A62A-BB3E-4911-AAAD-E5D2E202A986Q37357727-9F5E5C4A-76D9-4EF0-BE51-3C4CB74FB491Q37428179-5E63A795-AF34-4633-BD85-96A117F376E0Q37434694-70A36E45-18A0-4E50-8F31-567453196357Q37477751-C93AD067-A8B3-4977-87C4-F43D8A3FDF8CQ38012908-481E0F4B-066A-402B-9D21-0012D7D45BBCQ38202149-D5CA59B4-F186-45F0-907E-50B4CC5A0363Q38274969-2DF552E4-7C2D-4522-9014-454873681639Q38425357-C0BA9E07-32AD-4ECE-BA99-BC5191811B61Q38637363-5BB68A80-68A1-4DC2-A412-1BAEC7848856Q38701617-A4F386AE-2858-434E-93D6-7B2D47DD0762Q38820418-D39DEC28-5288-4D9A-9742-029E4E4A05F7Q38832001-021C28F0-1236-4C76-9F4B-E19F90F3EBB7Q38918147-02BF2A79-FBBE-4BAB-B67F-4A48E268E4BCQ39459129-62456DEF-4929-4AF3-95F4-79D41307FC6EQ39657304-BC394BE3-EC42-4835-BB04-6C57641F0673Q40914356-506241F6-5E96-4681-8D7E-FE052DE18D31Q42366987-083B5E82-A498-493E-9E0A-28A158624D62
P2860
Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Accumulation of trimethylamine ...... ents undergoing haemodialysis.
@en
Accumulation of trimethylamine ...... ents undergoing haemodialysis.
@nl
type
label
Accumulation of trimethylamine ...... ents undergoing haemodialysis.
@en
Accumulation of trimethylamine ...... ents undergoing haemodialysis.
@nl
prefLabel
Accumulation of trimethylamine ...... ents undergoing haemodialysis.
@en
Accumulation of trimethylamine ...... ents undergoing haemodialysis.
@nl
P2093
P356
P1476
Accumulation of trimethylamine ...... ients undergoing haemodialysis
@en
P2093
Allan M Evans
Gianfranco Fornasini
Marcus A Bain
Randall Faull
P304
P356
10.1093/NDT/GFK056
P407
P50
P577
2006-01-09T00:00:00Z